

# **Regarding Acquisition of Shares of Sakura Pharmacy Group**

AIN HOLDINGS INC.


**June 5, 2025**

# Deal Summary

On May 28, the share transfer agreement was signed for all the shares of Sakura Pharmacy Group.

Acquired shares	■ NISSK-WW Co., Ltd. (100% shares)
Contract date	■ May 28, 2025
Share transfer date	■ August, 2025 (scheduled)
Acquired group	■ Sakura Pharmacy Group
Number of shares acquired	■ 19,000,000,001 shares (100% ownership)
Acquisition price	■ ¥59,100 million
Financing plan	■ Borrowings from our Bank primarily


Figure of Capital Relationship



▶ The value is subject to change, since the final acquisition value is to be determined upon value adjustment after the closing, as defined in the share transfer agreement

# Positioning of This Initiative within the Medium- and Long-term Vision

This initiative is expected to enable us to achieve the target net sales of ¥700 billion for FY4/30, as outlined in the medium- and long-term vision "Ambitious Goals 2034", ahead of schedule.




- ▶ The total sales of the AIN Group (FY4/25) and the Sakura Pharmacy Group (FY3/24) is a simple sum
- ▶ The financial results of the Sakura Pharmacy Group for FY3/25 are currently undetermined
- ▶ We are currently assessing the impact of this initiative on full-year financial results for FY4/26. We will inform you as soon as the details are known

# Purpose of This Initiative

This initiative will significantly contribute to the “Top-line expansion,” which is the dispensing pharmacy business strategy outlined in the Medium- and Long-term Vision “Ambitious Goals 2034.”

## Top-line Expansion by Increasing the Number of Pharmacies


AIN Group	1,290 stores
Sakura Pharmacy Group	833 stores
Total	2,123 stores



► The number of pharmacies in the AIN Group as of the end of April 2025, and in the Sakura Pharmacy Group as of the end of March 2025

# Market Position after This Initiative

With the acquisition of the Sakura Pharmacy Group, our total sales of dispensing pharmacy business will exceed ¥500 billion, establishing us as the overwhelming leader in dispensing pharmacy industry in Japan.





▶ Based on latest disclosure materials

▶ The total sales of the AIN Group (FY4/25) and the Sakura Pharmacy Group (FY3/24) is a simple sum

# Financial Statements

The Sakura Pharmacy Group is scheduled to join us in August. The total net sales of the AIN Group and the Sakura Pharmacy Group would amount to approximately ¥600 billion, when simply summed. We are currently assessing the impact of this initiative on full-year financial results for FY4/26.

	 AIN GROUP	 SAKURA PHARMACY GROUP
(¥ billion)	FY4/25 results	FY3/24 results
Net sales	456.8	153.6
Operating income	16.8	12.7
% of net sales	3.7	8.3
Ordinary profit	18.0	6.8
% of net sales	3.9	4.4
Net income	9.2	3.6
% of net sales	2.0	2.3

▶ Based on disclosure materials

▶ The AIN Group's figures are actual results for FY4/25, and the Sakura Pharmacy Group's figures are actual results for FY3/24

**Inquiries related to this presentation should be addressed to**

**AIN HOLDINGS INC.  
Corporate Planning Division  
TEL(81)3-5333-1812  
<https://www.ainj.co.jp/corporate/>**

This document may not be reproduced or distributed to any third party without prior approval of AIN HOLDINGS INC. This document has been prepared for information purpose only and does not form part of a solicitation to sell or purchase any securities. Information contained herein may be changed or revised without prior notice. This document may contain forecasting statements as to future results of operations. No forecast statement can be guaranteed and actual results of operations may differ from those projected



AIN GROUP